Purpose: The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, monitoring, and dosage and administration of enteric-coated (EC) mycophenolate sodium are reviewed.

Please provide your email address to receive an email when new articles are posted on . Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves ...

Please provide your email address to receive an email when new articles are posted on . A retrospective analysis showed that patients with recalcitrant morphea benefited from mycophenolate therapy, ...

Substantial evidence exists that patients with scleroderma have immune dysfunction and autoimmunity, and several studies support the use of immunosuppressive treatment in these patients. Nihtyanova et ...

The use of mycophenolate mofetil (MMF) for prophylaxis of aGVHD and/or for treatment of acute or chronic GVHD is increasing. However, the benefit of MMF as an alternative to commonly used ...

Discover comprehensive details about Mycophenolate Mofetil, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...

Children with frequently relapsing or steroid-dependent nephrotic syndrome had a significantly longer relapse-free survival period with tacrolimus than with mycophenolate mofetil. Relapse-free ...

Review the side-effects of Mycophenolate Mofetil as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis. A ...

The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...

The most common adverse effects of EC mycophenolate sodium reported in Phase III clinical studies are GI effects, including nausea, vomiting, and diarrhea. [30] GI complaints are some of the most ...